Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over

Selumetinib (Koselugo, AstraZeneca) has a marketing authorisation in the UK for the 'treatment of symptomatic, inoperable plexiform neurofibromas in paediatric patients with neurofibromatosis type 1 aged 3 years and above'.

The dosage schedule is available in the summary of product characteristics for selumetinib.

The price for selumetinib is £4,223.59 for a 10‑mg 60‑capsule pack and £10,560.00 for a 25‑mg 60‑capsule pack (excluding VAT; company submission). The company has a commercial arrangement. This makes selumetinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.